5-Amino-1MQ and SLU-PP-332: separating hype from actual data

What did @mommycurrie actually say?

The creator claimed a customer lost "7.4 pounds in seven days and two inches off my waist" using a supplement combining 5-Amino-1MQ and SLU-PP-332, which she nicknamed "bikini in a bottle." She positioned these compounds as a safer alternative to semaglutide, saying they work "without the hair loss, the nausea, the muscle decline." She said 5-Amino-1MQ supports NAD+ levels to boost cellular energy and fat burning, while SLU-PP-332 triggers AMPK, your "master metabolic switch," to reduce inflammation and increase fat oxidation. She also floated claims about improved insulin sensitivity and collagen production. The pitch ended with a classic urgency hook: "before it all sells out."

To be clear, she is describing unregulated research compounds being sold in tablet form, and she is attributing dramatic, measurable body composition changes to them over the course of a single week.

Does the science back this up?

For 5-Amino-1MQ, there is some legitimate early science. For SLU-PP-332, human data is essentially nonexistent. Neither compound has clinical trial data supporting the claims made in this video.

5-Amino-1MQ is an NNMT (nicotinamide N-methyltransferase) inhibitor. Research in mice, including work by Kannt et al. (2018, Scientific Reports), showed NNMT inhibition reduced fat mass and improved metabolic markers. That is promising. But mouse models do not translate directly to human outcomes, and no peer-reviewed human trials on 5-Amino-1MQ for fat loss currently exist.

SLU-PP-332 is an ERR (estrogen-related receptor) agonist studied primarily for its AMPK-adjacent effects on muscle endurance. A 2023 study by Deng et al. in Nature Communications showed SLU-PP-332 improved exercise endurance in sedentary mice, essentially mimicking some effects of aerobic exercise at the cellular level. That is interesting science. It is not a human fat-loss clinical trial.

The claim that AMPK activation directly translates to measurable fat loss in humans over seven days, through an oral tablet, is not supported by any published evidence.

What did they get wrong (or right)?

The AMPK framing is not entirely wrong. But the leap from mechanism to outcome is enormous, and the creator does not flag that gap.

What they got directionally right: AMPK is genuinely involved in fat oxidation and metabolic regulation. NAD+ metabolism is a legitimate area of longevity and metabolic research. NNMT inhibition does have a plausible mechanistic connection to fat mass reduction based on preclinical data. These are real concepts, not invented ones.

What they got wrong, plainly: The 7.4 pounds in seven days framing is not credible as a fat-loss number. That scale of weight loss in one week almost certainly reflects water and glycogen loss, not fat tissue. Presenting it as evidence that these peptides "work" is misleading, whether or not that was the intent.

• Comparing these compounds to semaglutide without acknowledging that semaglutide has extensive Phase 3 clinical trial data and these compounds have none is a false equivalence.
• The collagen production claim came with an "I don't know about you" hedge, which is the creator's way of floating an unsupported claim with plausible deniability.
• Neither compound is FDA-approved, and their long-term safety profiles in humans are unknown.

What should you actually know?

These are research-stage compounds being sold directly to consumers, and that gap between lab and retail shelf matters.

Both 5-Amino-1MQ and SLU-PP-332 are available through research chemical suppliers and some compounding-adjacent telehealth platforms. Neither has completed human clinical trials for fat loss. The fact that they are described as "amino-based peptides" rather than drugs does not change their regulatory or safety profile. Mechanism-of-action claims, even accurate ones, are not the same as clinical evidence that a product works safely in your body at a given dose over a given time period.

If you are a woman over 40 dealing with midlife metabolic changes, that is a real and frustrating experience. But the urgency framing, "before it all sells out," combined with a single anecdotal result is a sales tactic, not a health recommendation. A one-week weight drop of 7.4 pounds is almost never adipose tissue. It is water. Anyone who tells you otherwise is either uninformed or not being straight with you.

Consult a licensed provider before using any unregulated peptide compound. The preclinical science here is genuinely interesting, but interesting science and safe consumer products are two very different things.